Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits (Memento-Plus)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04111211|
Recruitment Status : Recruiting
First Posted : October 1, 2019
Last Update Posted : February 21, 2021
Dementia is a clinical syndrome that is the result of distinct underlying pathologies including Alzheimer's disease (AD). Despite more than two decades of research on prevention and treatment of dementia and aging-related cognitive decline, highly effective preventive and therapeutic strategies remain elusive.
Many features of dementia render it especially challenging. Indeed development of disease occurs insidiously over the course of years or decade. In addition, the causes of dementia and determinants of its severity are likely multi-factorial.
To overcome these challenges and better understand the causes and course of AD and related disorders, long term follow-up studies of persons at high risk of dementia are required including multidimensional and harmonized assessment of risk factors, phenotypes (cognition, neuropsychiatric symptoms, physical health, self rated health) and endophenotypes (blood markers, genetic markers, neuroimaging markers).
This project proposes an extension of the follow-up of Memento participants over 5 to 10 years with of focus on cognitive outcomes and comorbidities.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits|
|Actual Study Start Date :||December 3, 2019|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2024|
|Individuals at high risk of developing Alzheimer's dementia|
- Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease) [ Time Frame: Each 12 months from baseline for 5 years ]
- Mortality [ Time Frame: Each 12 months from baseline for 5 years ]
- Loss of autonomy based on functional activity assessment [ Time Frame: Each 12 months from baseline for 5 years ]
- Rate of cognitive decline based on change in cognitive performances [ Time Frame: Each 12 months from baseline for 5 years ]
- Incidence of neurovascular and cardiovascular events (Stroke and Coronary events) [ Time Frame: Each 12 months from baseline for 5 years ]
- Quality of life: EQ-5D (EUROQOL) [ Time Frame: Each 12 months from baseline for 5 years ]EQ-5D (EUROQOL) questionnaire Subscales: VAS patient's self-rated health (0=worst, 100=best), mobility, self-care, usual activities, pain/discomfort and anxiety/depression (rated as no problems, slight problems, moderate problems, severe problems and extreme problems)
- Incidence of prodromal AD (Pre-symptomatic dementia) [ Time Frame: Each 12 months from baseline for 5 years ]
- Incidence of institutionalization [ Time Frame: Each 12 months from baseline for 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04111211
|Contact: Geneviève CHENE, Prof||(0)5 57 57 13 92 ext +firstname.lastname@example.org|
|Contact: Carole DUFOUIL, Director||(0)5 57 57 14 23 ext +email@example.com|
|Principal Investigator:||Geneviève CHENE, Prof||CIC-1401 EC - ISPED - CHU de Bodeaux|
|Study Chair:||Geneviève CHENE, Prof||CIC-1401 EC - ISPED - CHU de Bodeaux|
|Study Director:||Carole DUFOUIL, Director||CIC-1401 EC - ISPED - CHU de Bodeaux|